Latest Content

Maintenance with chidamide and azacitidine generated high 3-year overall survival and a low relapse incidence in high-risk AML after allogeneic transplant.

In a phase 2 study, adding venetoclax to ibrutinib rendered BTK C481X resistance mutations undetectable in patients with CLL.

Both the reactive and proactive ibrutinib dose-adjustment cohorts of the phase 2 TAILOR study met the primary ORR end point in previously untreated CLL.

Afami-cel received full FDA approval for unresectable or metastatic synovial sarcoma after prior chemotherapy.

PFS was improved only numerically with the use of maintenance dostarlimab vs observation after chemoradiation in high-risk locally advanced cervical cancer.

Eleven Western New York organizations received funding to advance cancer prevention and early detection.

China’s NMPA has satri-cel for pretreated, CLDN18.2-positive, HER2-negative advanced gastric/GEJ adenocarcinoma.

The STELLAR-303 trial met its OS end point with the zanzalintinib regimen in the ITT population but failed to show the same benefit in the NLM subgroup.

Callisia N. Clarke, MD, MS, FACS, FSSO, discusses how earlier alignment between surgeons and medical oncologists on systemic therapy use allows more patients to undergo resection.

Public libraries will play a role in attaining essential reading skills, improving financial literacy, and achieving a degree of critical thinking.

Six-year GARNET data show durable responses with dostarlimab in dMMR/MSI-H endometrial cancer.

The FDA accepted for review a sBLA for subcutaneous mosunetuzumab plus polatuzumab vedotin in LBCL, a BLA for ozekibart in chondrosarcoma, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.